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Abstract
Background: Miliary tuberculosis (TB) is an uncommon cause of acute respiratory distress syndrome (ARDS) with a
high mortality. The aim of the present study was to evaluate the clinical characteristics, predictors and outcome of
patients with ARDS caused by miliary TB.
Methods: A retrospective study was conducted among patients with a diagnosis of ARDS with miliary TB in four
hospitals from 2006 to 2010. Medical records and laboratory examinations of these patients were taken during the
first 24 h of admission.
Results: Eighty-five patients with miliary TB developed ARDS, 45 of whom survived (52.9%). The median age was
36.6 ± 12.5 years with 38 males (44.7%). Diabetes mellitus (DM) was the most common underlying disease (18.8%).
ICU mortality was 47.1%. The time from admission to anti-tuberculosis therapy was 4.5 ± 2.0 days. Mean duration of
mechanical ventilation was 8.5 ± 3.0 days in all patients. Duration of time to diagnosis, time from diagnosis to
mechanical ventilation, and time to anti-tuberculosis therapy were significantly shorter in survivors than those in
non-survivors. Diabetes mellitus (OR 5.431, 95%CI 1.471-20.049; P = 0.005), ALT (70-100U/L, OR 10.029, 95%CI 2.764-
36.389; P = 0.001), AST (>94U/L,OR 8.034, 95%CI 2.200-29.341; P = 0.002), D-dimer (>1.6mg/L, OR 3.167, 95%CI 0.896-
11.187; P = 0.042), hemoglobin (<90g/L, OR 14.824, 95%CI 3.713-59.179; P = 0.001), albumin (<25g/L, OR 15.896, 95%
CI 3.975-63.566; P = 0.001) were independent predictors of ARDS development in the setting of miliary TB.
Conclusions: Accurate diagnosis, early initiation of anti-tuberculosis therapy and mechanical ventilation are
important for the outcome of patients with ARDS caused by miliary TB. DM, ALT, AST, D-dimer, hemoglobin, and
albumin are independent predictors of ARDS development in patients with miliary TB.
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Background
Tuberculosis(TB) remains a major and global health dis-
ease[1,2]. Recent studies have shown the link between
acute respiratory distress syndrome (ARDS) and pulmon-
ary TB[3,4]. Pulmonary TB complicated by ARDS is often
found in the setting of miliary TB[3-6]. Most reports on
ARDS caused by miliary TB are small numbers of patients
in the case reports. Compared with miliary TB alone, mil-
iary TB with ARDS portends a higher mortality of 33-90%
[7-9]. Duration of miliary TB beyond 20 days tends to
markedly increase the risk of ARDS [10]. It is very import-
ant for recognition of ARDS caused by miliary TB.
Despite being a well-documented entity, miliary TB
complicated by ARDS remains a challenging diagnosis due
to its variable clinical manifestations and low morbidity.
Some predictors such as AST, and ALT[4,10] in miliary
TB with ARDS have drawn our attention. Numerous case
reports have mentioned that TB with ARDS is more
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common than TB complicated by anemia[4,11] and hypo-
proteinemia[6,11]. Thus, identifying the predictors of mil-
iary TB associated with ARDS can play an important role
in diagnosis and therapy. The aim of the present study was
to determine the predictors and their impact on outcome
based on a retrospective analysis of patients with ARDS
caused by miliary TB in four hospitals of Chongqing in
China, with the hope that this will contribute to a better
understanding and improved management of the disease.
Methods
Study design
Over a 5-year period (2006.03.31-2010.03.31), 16238
patients were admitted with a diagnosis of pulmonary
TB in the respiratory departments of Second Affiliated
Hospital of Chongqing Medical University, First
Affiliated Hospital of Chongqing Medical University,
Chest Hospital and Pulmonary Hospital in Chongqing,
China. Of these, 471 patients were diagnosed with
miliary TB. Five patients were excluded for further
analysis due to transfer to another hospital within 2
days. Of the remaining 466 patients, 85 patients
developed ARDS were admitted to the ICU during
the study period. The patients with ARDS caused
by miliary TB were divided into survivor group
(n = 45) and non-survivor group(n = 40).
Our research protocol was approved by the institu-
tional review boards of all participating institutions.
Data collection
The original case records including clinical profiles and la-
boratory parameters at admission were gathered from the
registration departments. Age, sex, past medical history,
underlying diseases, PaO2/FiO2, time from diagnosis to
mechanical ventilation, time from admission to anti-
tuberculosis therapy, duration of time to diagnosis, and
lengths of stay in the ICU and in the hospital were col-
lected. Acute Physiology and Chronic Health Evaluation
(APACHE) III score were calculated on the day of diagno-
sis with ARDS. The results of acid-fast bacilli(AFB) smears,
culture of respiratory specimens including sputum, tra-
cheal aspirate or bronchoalveolarlavage (BAL)fluid and
histopathological examination were recorded. Laboratory
data including aspartate aminotransferase (AST), alanine
aminotransferase (ALT), erythrocyte sedimentation rate
(ESR), D-dimer, hemoglobin, and albumin were taken dur-
ing the first 24 h of admission.
Definition
The diagnosis of miliary TB was made based on: equality
of the size, distribution, density miliary-like nodules bilat-
erally diffused on chest radiography by at least 2 independ-
ent of radiologists. Pulmonary TB was confirmed by at
least one of the three following criteria:1)positive AFB
smear and/or culture for M. tuberculosis from respiratory
specimes;2) histopathological identification of TB granulo-
main in biopsied tissues of lung, and/or pleura;3)clinical
and radiographic improvement after anti-tuberculosis
treatment[4]. The diagnosis of ARDS was made in accord-
ance to the diagnostic criteria of European-American
Consensus Conference on ARDS[12]:acute in onset with
PaO2/FiO2≤ 200mmHg, bilateral infiltrates seen on chest
radiograph, and pulmonary artery wedge pressure≤ 18
mm Hg. Survivors were defined as patients who survived
to discharge from hospital. Patients with human immuno-
deficiency virus (HIV), H1N1 Influenza A,and procalcito-
nin (PCT) positive were excluded.
Statistical analysis
Continuous variables were presented as mean ± standard
deviation(SD) or median and compared using an un-
paired t-test and the Mann–Whitney U test. Categorical
variables were compared using the Chi-squared test.
Multivariate logistic regression analysis was performed
to determine the predictors. All statistical analysis were




Patients’ clinical characteristics and outcome are presented
in Table 1. All patients experience typical symptoms of
miliary TB. Diabetes mellitus (DM) was the most common
underlying disease (18.8%). Thirty-three (38.8%) patients
had been initially misdiagnosed with viral pneumonia,
hypersensitivity pneumonitis, acute interstitial
pneumonia, fungal pneumonia, alveolar cell carcinoma, or
meningitis for a median of 7.2± 3.4 days from admission.
The diagnosis of miliary TB was established by AFB smear
and/or culture of respiratory specimens (including spu-
tum,tracheal aspirate or BAL fluid) in 61 patients(71.8%),
by histopathological examination of tissue biopsy in 11
patients(12.9%), and by clinicoradiological diagnosis in 13
patients(15.3%). Bacterial isolate drug sensitivity data were
available from 43 patients (50.6%), 3(3.5%) demonstrated
at least single drug resistance.
Hospital course and outcome
The time from admission to anti-tuberculosis therapy was
4.5±2.0 days. All 85 patients with ARDS were prescribed
anti-tuberculosis medication consisting of isoniazid,
rifampicin, ethambutol, and pyrazinamide. Mechanical ven-
tilation was necessary in all 85 patients. Thirty-eight
patients(44.7%) required invasive mechanical ventilation
while the rest were given non-invasive mechanical venti-
lation with BiPAP. Mean duration of mechanical ventila-
tion was 8.5 ± 3.0 days with ICU mortality of 47.1%.
Thirty-five patients (41.2%) received glucocorticoid
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therapy (methylprednisolone:80 mg/day) intravenously
for a maximum of 5 days when anti-tuberculosis therapy
was started. The use of glucocorticoids was associated
with a mortality of 22.9% (8/35) compared with 76.0%
(38/50) in those who were not treated with glucocorti-
coids. Comparison between patients with miliary TB
developing ARDS and patients with miliary TB alone are
shown in Table 2. Comparison between survivors and
non-survivors of ARDS patients are shown in Table 3.
Duration of time to diagnosis, time from diagnosis to
mechanical ventilation, and time from admission to
anti-tuberculosis therapy were significantly shorter in
survivors than non-survivors. Also, DM, ALT, AST, D-
dimer, hemoglobin, and albumin showed significant dif-
ference between the survivor group and non-survivor
group. The 3 pregnant patients underwent termination
of pregnancy, one of whom died of respiratory failure.
Predictors of ARDS development caused by military TB
Positive likelihood ratio were performed to analyze sensi-
tivity and specificity of the predictors level(the greater
the ratio the greater probability of true positive in a
positive result) (Table 4). On multivariate logistic regres-
sion analysis, presence of DM(OR 5.431, 95%CI 1.471-
20.049; P = 0.005),ALT (70-100U/L, OR 10.029, 95%CI
2.764-36.389; P = 0.001), AST (>94U/L,OR 8.034, 95%CI
2.200-29.341; P = 0.002), D-dimer (>1.6mg/L, OR 3.167,
95%CI 0.896-11.187; P = 0.042), hemoglobin (<90g/L,
OR 14.824, 95%CI 3.713-59.179; P = 0.001), albumin
(<25g/L, OR 15.896, 95%CI 3.975-63.566; P = 0.001)
Table 1 Clinical characteristics, investigations and
outcome of patients with ARDS caused by miliary TB
(n = 85)
Parameters Results
Age (years) 36.6 ± 12.5
Sex (male) 38(44.7%)
Clinical findings
Fever, cough, dyspnoea, weight loss 85 (100)
Diabetes mellitus 16 (18.8)
Past history of tuberculosis 9(10.6)





APACHE III score 71.6 ± 21.9
PaO2/FiO2(mmHg) 146.4 ± 34.5
Outcome
Duration of symptoms (days) 16.1 ± 5.2
Misdiagnosis for other diseases 33 (38.8)
Time to diagnosis (days) 7.2 ± 3.4
Length of stay in the ICU(days) 15.3 ± 3.5
Length of stay in the hospital(days) 26.7 ± 4.6
Duration of mechanical ventilation (days) 8.5 ± 3.0
Time from admission to anti-tuberculosis therapy (days) 4.5 ± 2.0
Glucocorticoids therapy 35 (41.2)
ICU mortality 40(47.1)
Data are presented as mean+ SD or n(%).
Table 2 Comparisons of demographic parametres, clinical
and laboratory characteristics between ARDS group and
non-ARDS group
ARDS(n=85) non-ARDS(n =381) P-value
Age(years) 36.6 ± 12.5 38.1 ± 11.9 0.892
Sex(male) 38(44.7%) 113(40.2%) 0.710
ALT (U/L) 73.7 ± 20.9 30.9 ± 25.8 0.001
AST (U/L) 94.7 ± 18.2 35.7 ± 23.1 0.001
ESR(mm/the first hour) 40.3 ± 18.8 42.8 ± 28.6 0.653
D-dimer (g/L) 1.2 ± 0.5 0.3 ± 0.2 0.001
Hemoglobin (g/L) 83.5 ± 16.2 125.4 ± 35.4 0.011
Albumin (g/L) 29.3 ± 3.7 40.2 ± 14.1 0.001
Data are presented as mean+ SD or n (%).AST: aspartate aminotransferase;
ALT: alanine aminotransferase. ESR:erythrocyte sedimentation rate.
Table 3 Comparisons of demographic parametres, clinical
and laboratory characteristics between survivors and







Age(years) 35.8 ± 9.5 37.1 ± 14.2 0.899
Sex(male) 20(44.4) 18(45) 0.745
DM 4(8.89) 12(30) 0.017
APACHE III score 70.4 ± 23.6 72.8 ± 19.1 0.856
PaO2/FiO2(mmHg) 149.5 ± 37.8 143.7 ± 31.9 0.648
Time to diagnosis (days) 3.2 ± 2.7 11.8 ± 4.1 0.002
Time from diagnosis to
mechanical ventilation (days)
2.5 ± 3.4 8.6 ± 5.3 0.034
Time from admission
to anti-tuberculosis therapy (days)
2.8 ± 1.6 6.9 ± 3.8 0.046
Length of stay in
the ICU(days)
19.3 ± 4.9 12.4 ± 3.2 0.267
Length of stay in the
hospital(days)
29.4 ± 5.6 17.3 ± 4.2 0.366
ALT (U/L) 56.2 ± 19.6 93.2 ± 22.4 0.038
AST (U/L) 63.8 ± 18.1 118.2 ± 21.4 0.019
ESR(mm/the first hour) 40.0 ± 18.1 40.6 ± 18.9 0.714
D-dimer (g/L) 0.6 ± 0.8 1.8 ± 0.6 0.017
Hemoglobin (g/L) 92.7 ± 14.8 76.2 ± 20.9 0.032
Albumin (g/L) 34.6 ± 3.9 23.9 ± 3.2 0.027
Data are presented as mean± SD or n(%).AST: aspartate aminotransferase; ALT:
alanine aminotransferase; ESR:erythrocyte sedimentation rate; DM:diabetes
mellitus.
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were independent predictors of ARDS development
caused by military TB.
Discussion
In the present study,our results demonstrated accurate
diagnosis and early therapeutic management were crucial
to optimizing outcome and DM, ALT, AST, D-dimer,
hemoglobin, and albumin are independent predictors of
ARDS development in patients with miliary TB. Tuber-
culosis remains a major cause of morbidity and mortality
around the world, especially in developing countries
[13,14]. According to the 13th annual tuberculosis report
of the World Health Organization (WHO), there were
an estimated 9.27 million new cases worldwide in 2007,
an increase from 9.24 million in 2006[1]. Further, miliary
TB is an uncommon cause of ARDS with a high
mortality [4,15]. The current study was performed in
Chongqing, the fourth central municipality of China,
which has a prevalence rate of 0.54%, higher than the na-
tional average. In our study, the average age of patients
with ARDS caused by miliary TB was younger than that
previously reported due to the possible reason of host
factors including region, race, and environment [3,4].
Mechanical ventilation is an important treatment for mil-
iary TB complicated by ARDS. Prompt mechanical ventila-
tion from the day of diagnosis can effectively improve
outcome, which benefits for the management of ARDS
caused by miliary TB. Also, accurate diagnosis and early
anti-tuberculosis therapy are crucial to the treatment of
miliary TB with ARDS. However, the high overall mortality
is attributed to case mix, misdiagnosis, and severity of ill-
ness, which ultimately lead to the delay in the initiation of
anti-tuberculosis therapy or mechanical ventilation.
Albumin plays an important role in regulating
plasma osmolality. Hypoproteinemia accelerates fluid
exudation, promotes alveolar edema, and contributes
to ventilation-perfusion imbalance. Also, in infected
mycobacterium tuberculosis, inflammatory cells accu-
mulate in the alveolar spaces, releasing granular
enzymes and oxidants which participate in local in-
flammation and overlapping reactions and damaging
the alveolar basement which allows increase in cellu-
lar permeability that aggravates oxygen dysfunction
and consequently causes ARDS [16,17]. If the process
continues, cytokines activate an inflammatory cascade
reaction and lead to other organs dysfunction, result-
ing in increases in AST and ALT. The changes in
AST, ALT, and serum albumin were significantly dif-
ferent between survivor and non-survivor groups. The
results showed that AST, ALT, and serum albumin
could be independent predictors of ARDS develop-
ment in miliary TB.
A number of studies have documented anemia asso-
ciated with TB[18-20]. It is well established that erythro-
poiesis is suppressed by inflammatory mediators in
anemia of chronic infection or inflammation and anemia
caused by chronic infections including TB results from
the effects of cytokines that mediate the inflammatory
response,which may provides the development for ARDS
[21-23]. As we know,the severity of anemia is mainly
determined by hemoglobin level. The decrease in
hemoglobin is assumed as a reflection of inflammation,
which can explain the relationship between ARDS and
hemoglobin in our study. This relationship is supported
by our finding of hemoglobin being an independent pre-
dictor of ARDS development in miliary TB.
D-dimer is a fibrin degradation product formed during
fibrinolysis, the process of breaking down a blood/fibrin
clot. Our study showed that D-dimer was an independ-
ent predictor of ARDS development and mortality.
Table 4 The levels of predicators for ARDS development
caused by military TB
Predicators Sensitivity Specificity Positive
likelihood ratio
ALT
Level1 41.9% 4.8% 0.44
Level 2 19.4% 96.3% 5.24
Level 3 25.8% 99.7% 86.00
Level 4 12.9% 99.1% 14.33
AST
Level1 32.2% 8.5% 0.35
Level 2 22.6% 96.0% 5.65
Level 3 29.0% 96.0% 7.25
Level 4 16.1% 99.4% 26.83
D-dimer
Level1 64.5% 23.7% 0.84
Level 2 25.8% 76.8% 1.11
Level 3 3.2% 99.4% 5.33
Level 4 6.5% 100% +∞
Hemoglobin
Level1 22.6% 8.2% 0.25
Level 2 19.4% 93.5% 2.98
Level 3 22.6% 98.9% 20.55
Level 4 35.5% 99.4% 59.16
Albumin
Level1 16.1% 5.6% 0.17
Level 2 58.1% 96.3% 15.70
Level 3 12.9% 98.6% 9.21
Level 4 12.9% 99.4% 21.50
ALT:Level 1:0-40U/L;Level 2:40-70U/L;Level 3:70-100U/L;Level 4:> 100U/L.
AST:Level 1:< 34U/L;Level 2:34-64U/L;Level 3:64-94U/L;Level 4:> 94U/L.
D-dimer:Level 1:< 0.34mg/L;Level 2:0.34-1.0mg/L;Level 3:1.0-1.6mg/L;Level
4:> 1.6mg/L;
Hemoglobin:Level 1:110-160g/L;Level 2:100-110 g/L;Level 3:90-100 g/L;Level
4:< 90 g/L;
Albumin:Level 1:35-50 g/L;Level 2:30-35g/L;Level 3:25-30 g/L;Level 4:< 25 g/L.
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Hyperglycemia is known to have a proinflammatory
effect, and may be correlated with poor outcome in hos-
pitalized/critically ill patients. Consistent with this cor-
relation, odds ratio analysis after ARDS development
identified DM as a risk factor.
To further understand the accurate levels of the predic-
tors for predicting ARDS, we used stratified analysis for
each index. Positive likelihood ratio was included in the
study due to a combination of sensitivity and specificity to
reflect the reality of the indicators. ALT (>70-100U/L),
AST (> 94U/L), D-dimer (>1.6mg/L), hemoglobin (<90g/
L), and albumin (<25g/L) at the time of admission were in-
dependent predictors for ARDS development in the setting
of miliary TB. Simple miliary TB can damage organs, indu-
cing mild increases in ALT and AST, although these incre-
mental changes are too small to have any accuracy in
predicting the occurrence of ARDS. However, when one
develops ARDS, inflammatory mediators will seriously
damage the organs, resulting in significantly higher
increases in the indexes than those in simple miliary TB,
which may translate into higher accuracy for predicting
ARDS. Though ESR was significantly elevated in miliary
TB, it did not reach statistical significance in association
with ARDS. Our findings suggested that ESR has minimal
value in predicting ARDS.
In addition, for patients with miliary TB who devel-
oped ARDS during pregnancy, there are few case reports
with favorable outcome. Our data suggested that preg-
nancy was a risk factor for ARDS, but this clinical obser-
vation was limited by the small sample size. The efficacy
of systemic corticosteroids is well-documented for sev-
eral extrapulmonary complications of tuberculosis such
as tuberculous meningitis and tuberculous pericarditis
[24-28], as well as ARDS[29-32]. The role of glucocorti-
coids remains controversial in the management of mil-
iary TB complicated by ARDS[33,34]. In our study,
patients treated with glucocorticoids had a lower mortal-
ity than those who did not, which might suggest that
methylprednisolone at a dose of 80 mg/day was given
intravenously at the time when anti-tuberculosis therapy
was started might be benefit for ARDS associated with
miliary TB. The limitations of this study are studies with
large numbers of patients may be required to validate
the observations due to a relatively small sample size in
the present study.
Conclusions
In conclusion, the mortality of ARDS caused by miliary TB
remains high. Accurate diagnosis and early therapeutic
management of therapy including anti-tuberculosis agents
and mechanical ventilation are crucial to optimizing out-
come. DM, ALT, AST, D-dimer, hemoglobin, and albumin
are independent predictors of ARDS development in
patients with miliary TB.
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